Literature DB >> 7558811

Incidence of cervical metastasis from uveal melanoma: implications for treatment.

D Tojo1, B L Wenig, K I Resnick.   

Abstract

BACKGROUND: Although the literature has focused on the propensity of uveal melanoma to metastasize to the liver, little attention has been directed to its spread in regional, cervical lymph nodes.
METHODS: We reviewed records of 77 patients who underwent primary resection of uveal melanoma during a 15-year period at our institution.
RESULTS: A total of only 6.5% of patients developed cervical metastasis. Factors such as age, race, sex, tumor location, and histology were not influential in identifying these patients. Tumor size and local orbital recurrence were, however, associated with a higher risk of cervical lymphadenopathy (p < 0.05). Cervical metastases were also associated with the presence of distant metastatic disease.
CONCLUSION: Neck dissection should be reserved for patients with clinically demonstrable lymphadenopathy only after distant disease has been excluded.

Entities:  

Mesh:

Year:  1995        PMID: 7558811     DOI: 10.1002/hed.2880170211

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  2 in total

Review 1.  Imaging of ocular melanoma metastasis.

Authors:  Rashmi Balasubramanya; Santosh Kumar Selvarajan; Mougnyan Cox; Ganesh Joshi; Sandeep Deshmukh; Donald G Mitchell; Patrick O'Kane
Journal:  Br J Radiol       Date:  2016-05-31       Impact factor: 3.039

2.  Patients presenting with metastases: stage IV uveal melanoma, an international study.

Authors:  Gaurav Garg; Paul T Finger; Tero T Kivelä; E Rand Simpson; Brenda L Gallie; Svetlana Saakyan; Anush G Amiryan; Vladimir Valskiy; Kimberly J Chin; Ekaterina Semenova; Stefan Seregard; Maria Filì; Matthew Wilson; Barrett Haik; Josep Maria Caminal; Jaume Catala-Mora; Cristina Gutiérrez; David E Pelayes; Anibal Martin Folgar; Martine Johanna Jager; Mehmet Doğrusöz; Gregorius P M Luyten; Arun D Singh; Shigenobu Suzuki
Journal:  Br J Ophthalmol       Date:  2021-01-15       Impact factor: 4.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.